Fortress Biotech, Inc. (NASDAQ:FBIO) is expected to post earnings of -$0.21 per share


Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) to report earnings per share (EPS) of ($0.21) for the current fiscal quarter, according to Zacks. Five analysts provided earnings estimates for Fortress Biotech. The lowest EPS estimate is ($0.37) and the highest is ($0.06). Fortress Biotech reported earnings of ($0.11) per share in the same quarter last year, suggesting a negative year-over-year growth rate of 90.9%. The company is expected to release its next quarterly results on Monday, January 1.

According to Zacks, analysts expect Fortress Biotech to report annual earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($0. $30). For the next fiscal year, analysts expect the company to post earnings of $0.10 per share, with EPS estimates ranging from ($1.45) to $2.19. Zacks Investment Research EPS averages are an average average based on a survey of sell-side research companies that track Fortress Biotech.

Fortress Biotech Inc (NASDAQ:FBIO – Get Rating) last released its quarterly earnings data on Monday, March 28. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.08 per ($0.46). Fortress Biotech had a negative return on equity of 27.80% and a negative net margin of 94.06%.

FBIO has been the subject of several recent research reports. StockNews.com downgraded shares of Fortress Biotech from a “hold” rating to a “sell” rating in a Tuesday, March 29 research note. Roth Capital reaffirmed a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 research note. Zacks Investment Research downgraded shares of Fortress Biotech from a “held” rating to a “strong sell” rating in a Thursday, March 31 research note. Finally, TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 research note. Two equity research analysts rated the stock with a sell rating and four gave the company a buy rating. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.30.

FBIO traded $0.05 on Tuesday during trading hours, hitting $1.15. 823,173 shares of the company were traded, against an average volume of 501,767. Fortress Biotech has a 12-month low of $1.09 and a 12-month high of $5.05. The company has a 50-day moving average of $1.55 and a 200-day moving average of $2.37. The company has a market capitalization of $120.17 million, a P/E ratio of -1.46 and a beta of 2.29. The company has a current ratio of 3.43, a quick ratio of 3.33 and a debt ratio of 0.21.

Major investors have recently changed their positions in the company. Citigroup Inc. increased its position in Fortress Biotech shares by 160.5% in the third quarter. Citigroup Inc. now owns 8,879 shares of the biopharmaceutical company valued at $29,000 after buying an additional 5,470 shares in the last quarter. Marshall Wace LLP bought a new stock position in Fortress Biotech in Q4 worth $30,000. Two Sigma Securities LLC bought a new stock position in Fortress Biotech in Q3 worth $33,000. BNP Paribas Arbitrage SA increased its position in Fortress Biotech shares by 319.9% ​​in the third quarter. BNP Paribas Arbitrage SA now owns 12,459 shares of the biopharmaceutical company valued at $40,000 after buying an additional 9,492 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Fortress Biotech stock in Q4 worth $41,000. 30.77% of the shares are currently held by institutional investors.

Fortress Biotech Company Profile (Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

Featured articles

Get a Free Copy of Zacks’ Research Report on Fortress Biotech (FBIO)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Fortress Biotech (NASDAQ:FBIO)



Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.

About Sally Dominguez

Check Also

My Daughter’s Acne Was So Bad We Were Concerned About Her Mental Health

“My GP seemed eager to try all available treatments before referring me to a dermatologist …